Tests mevrometostat with enzalutamide in men with advanced prostate cancer
Tests mevrometostat plus enzalutamide, compared with placebo, in men with advanced prostate cancer.
Plain-language title generated from the registry record
Registry title: A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Key facts
- Where
- Gabrovo, Pleven, Plovdiv, Sofiya, and Stara Zagora, BulgariaSee the 5 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer that has spread and no longer responds to hormone lowering treatment, and who have not had certain earlier cancer treatments for this stage.
- Age
- 18 years and older
- Sex
- Men only
- Disease stage
- Prostate adenocarcinoma without small cell features, spread to bone or soft tissue, and getting worse despite medical or surgical castration (metastatic castration-resistant).
- Earlier treatment
- Must not have had treatment for this stage such as chemotherapy, radio-ligand therapy, CDK4/6 inhibitors, androgen receptor signaling inhibitors (including enzalutamide, apalutamide, darolutamide) or PARP monotherapy. First-generation antiandrogens, estrogens, progestins and cyproterone acetate are allowed. Docetaxel is allowed for earlier hormone-sensitive disease if the cancer did not progress during or within 3 months of treatment.
Main reasons for not taking part
- Known or suspected brain metastasis or active leptomeningeal disease, or a significant history of seizure
- Clinically significant heart or blood vessel disease
- Active inflammatory bowel disease, chronic diarrhea, or previous stomach removal or lap-band surgery
- Past myelodysplastic syndrome, acute myeloid leukemia, or another cancer (with a few exceptions)
- Inadequate organ function
Read by machine on 11 November 2026.
Where in Bulgaria
- Multiprofile Hospital For Active Treatment "Dr. Tota Venkova" ADGabrovo, BulgariaNo longer taking part
- University Multiprofile Hospital for Active Treatment Dr Georgi Stranski EADPleven, BulgariaNo longer taking part
- Complex Oncological Center - Plovdiv, EOODPlovdiv, BulgariaNo longer taking part
- University Multiprofile Hospital For Active Treatment Sofiamed OODSofiya, BulgariaNo longer taking part
- Complex Oncology Center Stara Zagora Ltd.Stara Zagora, BulgariaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT06629779EU 2024-511652-40-00
- Record updated
- 30 October 2026
- Original description
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.Read full original descriptionShow less
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Inclusion: Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features; Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan; Progressive disease in the setting of medical or surgical castration; ECOG performance status 0 or 1, with a life expectancy of ≥12 months as assessed by the investigator.
Exclusion: Known history of active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery; Participants must be treatment naïve at the mCRPC stage, eg, no cytotoxic chemotherapy, radio-ligand therapy (i.e. 177Lu- PSMA-617), CDK4/6 inhibitors, 5-alpha reductase inhibitors for prostate cancer in any setting, androgen receptor signaling inhibitors (ARSi) including enzalutamide, apalutamide, darolutamide, poly ADP-ribose polymerase (PARP) monotherapy or other systemic anti-cancer treatment with the following exceptions:; Treatment with first-generation antiandrogen (ADT) agents, estrogens, progestins, cyproterone acetate; Docetaxel treatment is allowed for mCSPC, as long as no signs of failure, or disease progression occurred during treatment or within 3 months of treatment completion; Previous administration with an investigational product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention (whichever is longer); Clinically significant cardiovascular disease; Known or suspected brain metastasis or active leptomeningeal disease or clinically significant history of seizure; Any history of myelodysplastic syndrome, acute myeloid leukemia, or any other prior malignancy with a few exceptions; Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that make the participant inappropriate for the study; Inadequate organ function.